FDA Recalls Pilocarpine Ophthalmic Solution Due to Incomplete Stability Studies
Akorn Inc. recalled all lots of Pilocarpine Hydrochloride Ophthalmic Solution 1% nationwide due to CGMP deviations. The firm went out of business and could not complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall for a prescription ophthalmic medication with unverified long-term stability due to incomplete testing. While no illnesses or injuries have been reported, the product represents a potential risk of harm because its safety and efficacy over its shelf life cannot be assured. This meets the criterion for a High severity recall as a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Akorn, Inc. is recalling all lots of Pilocarpine Hydrochloride Ophthalmic Solution, USP 1%, 15 mL bottles distributed nationwide in the USA and Puerto Rico. This is a Class II recall.
The recall was initiated due to current good manufacturing practice (CGMP) deviations. Specifically, the firm went out of business and could no longer continue the stability studies required to verify that the product remains safe and effective throughout its shelf life. Without completion of these stability studies, the product's long-term safety and efficacy cannot be assured.
The recalled product
- Product
- Pilocarpine Hydrochloride Ophthalmic Solution, USP 1%, 15 mL bottles, Rx Only, Sterile, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · unverified stability
See all →- HighPrescription eye solution recalled due to discontinued stability studies
FDA (Drugs) · 2023-06-07
- HighLorazepam Injection Recalled Due to Manufacturing Control Deviations
FDA (Drugs) · 2023-06-07
- HighAcetaminophen & Codeine Oral Solution Recalled Due to Unverified Stability
FDA (Drugs) · 2023-06-07
- HighLactulose Solution Recall Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-06-07
- ModerateAcyclovir Oral Suspension Recalled for Manufacturing Practice Deviations
FDA (Drugs) · 2023-06-07
Similar recalls
- ModerateAkorn Atropine Sulfate Eye Solution Recalled for Failed Stability Testing
FDA (Drugs) · 2023-02-15
- HighProparacaine Ophthalmic Solution Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-01-25
- SevereAkorn Recalls Phenylephrine Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- LowAkorn Recalls Atropine Sulfate Ophthalmic Solution Due to Viscosity Failure
FDA (Drugs) · 2018-03-14
- ModerateDrug recall: Proparacaine eye solution due to manufacturing deviations
FDA (Drugs) · 2023-01-25
- LowAkorn Recalls COSOPT Ophthalmic Solution Due to Stability Failures
FDA (Drugs) · 2019-02-20